An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA in Patients With Hypoparathyroidism
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Teriparatide (Primary) ; Parathyroid hormone
- Indications Hypoparathyroidism
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Entera Bio
- 10 Dec 2018 Planned End Date changed from 1 Dec 2018 to 21 Dec 2018.
- 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 08 May 2018 New trial record